[1]
|
毕向雁, 李和根, 马恰怡, 孙建立, 周蕾, 朱立峰, 蔡浦玉, 谭翔文. 一例肺腺鳞癌TKI治疗后病理转化报道[J]. 实用肿瘤杂志, 2021, 36(6): 571-574.
|
[2]
|
Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A. and Bray, F. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. https://doi.org/10.3322/caac.21660
|
[3]
|
Liang, J., Sui, Q., Zheng, Y., Bi, G., Chen, Z., Li, M., Huang, Y., Lu, T., Zhan, C. and Guo, W. (2020) A Nomogram to Predict Prognosis of Patients with Lung Adenosquamous Carcinoma: A Population-Based Study. Journal of Thoracic Disease, 12, 2288-2303. https://doi.org/10.21037/jtd.2020.03.115
|
[4]
|
Wang, J., Wang, Y., Tong, M., Pan, H. and Li, D. (2018) Research Progress of the Clinicopathologic Features of Lung Adenosquamous Carcinoma. OncoTargets and therapy, 11, 7011-7017. https://doi.org/10.2147/OTT.S179904
|
[5]
|
Li, Y., Wu, X., Huang, Y., Bian, D. and Jiang, L. (2020) 18F-FDG PET/CT in Lung Adenosquamous Carcinoma and Its Correlation with Clinicopathological Features and Prog-nosis. Annals of Nuclear Medicine, 34, 314-321.
https://doi.org/10.1007/s12149-020-01450-1
|
[6]
|
赵文君, 王旭, 马克威. 肺腺鳞癌研究进展[J]. 中华肿瘤杂志, 2017, 39(4): 241-244.
|
[7]
|
Zhu, L., Jiang, L., Yang, J., Gu, W. and He, J. (2018) Clinical Characteristics and Prog-nosis of Patients with Lung Adenosquamous Carcinoma after Surgical Resection: Results from two Institutes. Journal of Thoracic Disease, 10, 2397-2402. https://doi.org/10.21037/jtd.2018.03.186
|
[8]
|
周生余, 薛奇, 应建明, 胡兴胜, 杨建良, 林华, 石远凯. 肺腺鳞癌的临床病理和分子生物学特征及其预后影响因素分析[J]. 中华肿瘤杂志, 2019, 41(1): 50-55.
|
[9]
|
Pan, F., Cui, S., Wang, W., Gu, A. and Jiang, L. (2018) Survival Analysis for Lung Adenosquamous Carcinoma Patients with Brain Metastasis. Journal of Cancer, 9, 3707-3712. https://doi.org/10.7150/jca.27441
|
[10]
|
Borczuk, A.C. (2018) Uncommon Types of Lung Carcinoma with Mixed Histology: Sarcomatoid Carcinoma, Adenosquamous Carcinoma, and Mucoepidermoid Carcinoma. Archives of Patholo-gy and Laboratory Medicine, 142, 914-921.
https://doi.org/10.5858/arpa.2017-0584-RA
|
[11]
|
刘海波, 张诗杰. 肺腺鳞癌的临床现状及研究进展[J]. 中国综合临床, 2022, 38(4): 304-307.
|
[12]
|
Wu, X., Yu, W., Petersen, R.H., Sheng, H., Wang, Y., Lv, W. and Hu, J. (2020) A Competing Risk Nomogram Predicting Cause-Specific Mortality in Patients with Lung Adenosquamous Carcinoma. BioMed Central Cancer, 20, 429-439. https://doi.org/10.1186/s12885-020-06927-w
|
[13]
|
谢玉华, 李升锦. 肺腺鳞癌治疗研究进展[J]. 世界最新医学信息文摘, 2020, 20(27): 136-137, 140.
|
[14]
|
Li, H., Wang, Z., Yang, F. and Wang, J. (2020) Development and Validation of a Nomogram for Predicting Cancer-Specific Survival of Surgical Re-sected Stage I-II Adenosquamous Carcinoma of the Lung. Journal of Surgical Oncology, 121, 1027-1035. https://doi.org/10.1002/jso.25858
|
[15]
|
吴杰, 吴忠纯, 肖辉, 闫鹏, 王石川. 13例肺腺鳞癌的CT图像分析[J]. 山东医药, 2017, 57(47): 93-95.
|
[16]
|
Liu, Y., Zhu, Y., Bai, L., Chen, F., Wang, J. and Guo, Y. (2020) Adenocarcino-matous-Predominant Subtype Associated with a Better Prognosis in Adenosquamous Lung Carcinoma. BioMed Central Cancer, 20, 520-526.
https://doi.org/10.1186/s12885-020-06972-5
|
[17]
|
Li, C. and Lu, H. (2018) Adenosquamous Carcinoma of the Lung. OncoTargets and Therapy, 11, 4829-4835.
https://doi.org/10.2147/OTT.S164574
|
[18]
|
Song, Z., Yu, X. and Zhang, Y. (2017) Clinicopathological Characteris-tics and Survival of ALK, ROS1 and RET Rearrangements in Non-Adenocarcinoma Non-Small Cell Lung Cancer Pa-tients. Cancer Biology and Therapy, 18, 883-887.
https://doi.org/10.1080/15384047.2016.1235660
|
[19]
|
Cheng, Y., Yang, J., Wang, D. and Yan, D. (2022) ROS1 Fusion Lung Adenosquamous Carcinoma Patient with Short-Term Clinical Benefit after Crizotinib Treatment: A Case Report. Annals of Translational Medicine, 10, 157-162.
https://doi.org/10.21037/atm-21-6754
|
[20]
|
李廷, 赵丽萍, 胡佳楠, 虞伟妃, 周珏伊, 蓝燕丽, 符丹丽. 肺腺鳞癌伴脑转移患者的预后分析[J]. 浙江医学, 2019, 41(16): 1768-1771.
|
[21]
|
Hlaing, A.M., Furusato, B., Udo, E., Kitamura, Y., Souda, M., Masutani, M. and Fukuoka, J. (2018) Expression of Phosphatase and Tensin Homolog and Programmed Cell Death Ligand 1 in Adenosquamous Carcinoma of the Lung. Biochemical and Biophysical Research Communications, 503, 2764-2769. https://doi.org/10.1016/j.bbrc.2018.08.037
|
[22]
|
Kojima, K., Sakamoto, T., Ka-sai, T., Atagi, S. and Yoon, H. (2022) A Quantitative Evaluation of the Histological Type Dependence of the Pro-grammed Death-Ligand 1 Expression in Non-Small Cell Lung Cancer Including Various Adenocarcinoma Subtypes: A Cross-Sectional Study. Japanese Journal of Clinical Oncology, 52, 281-285.
https://doi.org/10.1093/jjco/hyab202
|
[23]
|
Zito Marino, F., Rossi, G., Montella, M., Botti, G., De Cecio, R., Mo-rabito, A., La Manna, C., Ronchi, A., Micheli, M., Salatiello, G., Micheli, P., Rocco, D., Accardo, M. and Franco, R. (2020) Heterogeneity of PD-L1 Expression in Lung Mixed Adenocarcinomas and Adenosquamous Carcinomas. Ameri-can Journal of Surgical Pathology, 44, 378-386.
https://doi.org/10.1097/PAS.0000000000001400
|
[24]
|
Liu, Y., Dong, Z., Jiang, T., Hou, L., Wu, F., Gao, G., He, Y., Zhao, J., Li, X., Zhao, C., Zhang, W., Tian, Q., Pan, Y., Wang, Y., Yang, S., Wu, C., Ren, S., Zhou, C., Zhang, J. and Hirsch, FR. (2018) Heterogeneity of PD-L1 Expression Among the Different Histological Components and Meta-static Lymph Nodes in Patients with Resected Lung Adenosquamous Carcinoma. Clinical Lung Cancer, 19, e421-e430. https://doi.org/10.1016/j.cllc.2018.02.008
|
[25]
|
Shi, X., Wu, S., Sun, J., Liu, Y., Zeng, X. and Liang, Z. (2017) PD-L1 Expression in Lung Adenosquamous Carcinomas Compared with the More Common Variants of Non-Small Cell Lung Cancer. Scientific Reports, 7, 46209-46215.
https://doi.org/10.1038/srep46209
|
[26]
|
Hu, M., Zhang, B., Xu, J., Wang, S., Zhao, Y., Zhang, L. and Han, B. (2019) Clinical Outcomes of Different Generations of EGFR Tyrosine Kinase Inhibitors in Advanced Lung Adenosquamous Carcinoma. Molecular Diagnosis and Therapy, 23, 773-779. https://doi.org/10.1007/s40291-019-00425-x
|
[27]
|
Cheng, Y., Zhang, Y., Yuan, Y., Wang, J., Liu, K., Yu, B., Xie, L., Ou-Yang, C., Wu, L. and Ye, X. (2021) The Comprehensive Analyses of Genomic Variations and Assessment of TMB and PD-L1 Expression in Chinese Lung Adenosquamous Carcinoma. Frontiers in Genetics, 11, Article 609405. https://doi.org/10.3389/fgene.2020.609405
|
[28]
|
Liu, Q., Wu, L. and Zhang, S. (2021) Transformation of Advanced Lung Adenocarcinoma to Acquired T790M Resistance Mutation Adenosquamous Carcinoma Following Tyrosine Kinase Inhibitor: A Case Report. Tumori Journal, 107, NP5-NP10. https://doi.org/10.1177/0300891620973262
|
[29]
|
Zhang, C., Yang, H., Lang, B., Yu, X., Xiao, P., Zhang, D., Fan, L. and Zhang, X. (2018) Surgical Significance and Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase In-hibitors in Patients with Primary Lung Adenosquamous Carcinoma. Cancer Management and Research, 10, 2401-2407. https://doi.org/10.2147/CMAR.S165660
|
[30]
|
Lin, G., Li, C., Li, P.S., Fang, W.Z., Xu, H.P., Gong, Y.H., Zhu, Z.F., Hu, Y., Liang, W.H. and Chu, Q. (2020) Genomic Origin and EGFR-TKI Treatments of Pulmonary Adenosqua-mouscarcinoma. Annals of Oncology, 31, 517-524.
https://doi.org/10.1016/j.annonc.2020.01.014
|
[31]
|
任昱恺, 林宗祥, 韦柏充, 杨洋. 基于SEER数据库肺腺鳞癌淋巴结转移预测模型的构建[J]. 河南医学研究, 2022, 31(7): 1198-1203.
|
[32]
|
李敏, 许伟, 陈艳, 吴双双, 吴剑卿. 高龄肺腺鳞癌患者免疫治疗一例并文献复习[J]. 中华老年医学杂志, 2020, 39(6): 689-692.
|
[33]
|
Ma, W., Duan, H., Zhang, R., Wang, X., Xu, H., Zhou, Q. and Zhang, L. (2019) High Expression of Indoleamine 2, 3-Dioxygenase in Adenosquamous Lung Carcinoma Correlates with Favorable Patient Outcome. Journal of Cancer, 10, 267-276. https://doi.org/10.7150/jca.27507
|
[34]
|
Zhu, Q., Luo, R., Gu, J., Hou, Y., Chen, Z., Xu, F., Wang, L., Mao, W., Lu, C. and Ge, D. (2020) High CXCR4 Expression Predicts a Poor Prognosis in Resected Lung Adenosqua-mous Carcinoma. Journal of Cancer, 11, 810-818.
https://doi.org/10.7150/jca.36498
|
[35]
|
Wang, Y., Qian, F., Hu, M., Chen, Y., Yang, Z. and Han, B. (2021) Clinical Significance of Visceral Pleural and Lymphovascular Invasion in Surgically Resected Adenosquamous Lung Cancer. European Journal of Cardio-Thoracic Surgery, 59, 617-623. https://doi.org/10.1093/ejcts/ezaa353
|